Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results

Federico Rea, Giuseppe Marulli, Luigi Bortolotti, Cristiano Breda, Adolfo Gino Favaretto, Lucio Loreggian, Francesco Sartori

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). A large experience served to evaluate the efficacy of surgery followed by adjuvant chemo-radiotherapy. Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. The aim of our study was to evaluate the feasibility of this protocol and to estimate survival. Methods: From 2000 to 2003, 21 patients with MPM (14 males and 7 females, median age 59 years) were enrolled in the prospective study. Induction chemotherapy consisted of Carboplatin (AUC 5 mg/mL/min on Day 1) and Gemcitabine (1000 mg/m2 on Days 1, 8, 15) for three to four cycles. EPP was performed 3-5 weeks after induction therapy, while post-operative RT was given 4-6 weeks after operation. Results: Ten patients received three cycles of chemotherapy, 10 patients received four cycles and 1 patient had two cycles. Grades 3-4 haematological toxicity occurred in eight (38.1%) patients. Chemotherapy response rate was: complete 0%, partial 33.3% and stable disease 66.7%. Seventeen (80.9%) out of 21 patients underwent EPP with no intra or post-operative mortality with an overall major and minor morbidity rate at 52.4%. Median survival was 25.5 months, with an overall 1, 3 and 5-year survival rate of 71, 33 and 19%, respectively. Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalLung Cancer
Volume57
Issue number1
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Induction Chemotherapy
Pneumonectomy
Thorax
Radiation
gemcitabine
Adjuvant Radiotherapy
Carboplatin
Survival
Morbidity
Therapeutics
Drug Therapy
Area Under Curve
Malignant Mesothelioma
Survival Rate
Prospective Studies
Mortality

Keywords

  • Induction chemotherapy
  • Malignant pleural mesothelioma
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM) : Feasibility and results. / Rea, Federico; Marulli, Giuseppe; Bortolotti, Luigi; Breda, Cristiano; Favaretto, Adolfo Gino; Loreggian, Lucio; Sartori, Francesco.

In: Lung Cancer, Vol. 57, No. 1, 07.2007, p. 89-95.

Research output: Contribution to journalArticle

Rea, Federico ; Marulli, Giuseppe ; Bortolotti, Luigi ; Breda, Cristiano ; Favaretto, Adolfo Gino ; Loreggian, Lucio ; Sartori, Francesco. / Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM) : Feasibility and results. In: Lung Cancer. 2007 ; Vol. 57, No. 1. pp. 89-95.
@article{6ccf0a7c18fb4d70bc443f5e974284a3,
title = "Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results",
abstract = "Background: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). A large experience served to evaluate the efficacy of surgery followed by adjuvant chemo-radiotherapy. Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. The aim of our study was to evaluate the feasibility of this protocol and to estimate survival. Methods: From 2000 to 2003, 21 patients with MPM (14 males and 7 females, median age 59 years) were enrolled in the prospective study. Induction chemotherapy consisted of Carboplatin (AUC 5 mg/mL/min on Day 1) and Gemcitabine (1000 mg/m2 on Days 1, 8, 15) for three to four cycles. EPP was performed 3-5 weeks after induction therapy, while post-operative RT was given 4-6 weeks after operation. Results: Ten patients received three cycles of chemotherapy, 10 patients received four cycles and 1 patient had two cycles. Grades 3-4 haematological toxicity occurred in eight (38.1{\%}) patients. Chemotherapy response rate was: complete 0{\%}, partial 33.3{\%} and stable disease 66.7{\%}. Seventeen (80.9{\%}) out of 21 patients underwent EPP with no intra or post-operative mortality with an overall major and minor morbidity rate at 52.4{\%}. Median survival was 25.5 months, with an overall 1, 3 and 5-year survival rate of 71, 33 and 19{\%}, respectively. Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.",
keywords = "Induction chemotherapy, Malignant pleural mesothelioma, Radiation therapy, Surgery",
author = "Federico Rea and Giuseppe Marulli and Luigi Bortolotti and Cristiano Breda and Favaretto, {Adolfo Gino} and Lucio Loreggian and Francesco Sartori",
year = "2007",
month = "7",
doi = "10.1016/j.lungcan.2007.02.004",
language = "English",
volume = "57",
pages = "89--95",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM)

T2 - Feasibility and results

AU - Rea, Federico

AU - Marulli, Giuseppe

AU - Bortolotti, Luigi

AU - Breda, Cristiano

AU - Favaretto, Adolfo Gino

AU - Loreggian, Lucio

AU - Sartori, Francesco

PY - 2007/7

Y1 - 2007/7

N2 - Background: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). A large experience served to evaluate the efficacy of surgery followed by adjuvant chemo-radiotherapy. Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. The aim of our study was to evaluate the feasibility of this protocol and to estimate survival. Methods: From 2000 to 2003, 21 patients with MPM (14 males and 7 females, median age 59 years) were enrolled in the prospective study. Induction chemotherapy consisted of Carboplatin (AUC 5 mg/mL/min on Day 1) and Gemcitabine (1000 mg/m2 on Days 1, 8, 15) for three to four cycles. EPP was performed 3-5 weeks after induction therapy, while post-operative RT was given 4-6 weeks after operation. Results: Ten patients received three cycles of chemotherapy, 10 patients received four cycles and 1 patient had two cycles. Grades 3-4 haematological toxicity occurred in eight (38.1%) patients. Chemotherapy response rate was: complete 0%, partial 33.3% and stable disease 66.7%. Seventeen (80.9%) out of 21 patients underwent EPP with no intra or post-operative mortality with an overall major and minor morbidity rate at 52.4%. Median survival was 25.5 months, with an overall 1, 3 and 5-year survival rate of 71, 33 and 19%, respectively. Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.

AB - Background: Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). A large experience served to evaluate the efficacy of surgery followed by adjuvant chemo-radiotherapy. Trimodality therapy results have led us to test induction chemotherapy followed by EPP and adjuvant radiotherapy in stages I-III of MPM. The aim of our study was to evaluate the feasibility of this protocol and to estimate survival. Methods: From 2000 to 2003, 21 patients with MPM (14 males and 7 females, median age 59 years) were enrolled in the prospective study. Induction chemotherapy consisted of Carboplatin (AUC 5 mg/mL/min on Day 1) and Gemcitabine (1000 mg/m2 on Days 1, 8, 15) for three to four cycles. EPP was performed 3-5 weeks after induction therapy, while post-operative RT was given 4-6 weeks after operation. Results: Ten patients received three cycles of chemotherapy, 10 patients received four cycles and 1 patient had two cycles. Grades 3-4 haematological toxicity occurred in eight (38.1%) patients. Chemotherapy response rate was: complete 0%, partial 33.3% and stable disease 66.7%. Seventeen (80.9%) out of 21 patients underwent EPP with no intra or post-operative mortality with an overall major and minor morbidity rate at 52.4%. Median survival was 25.5 months, with an overall 1, 3 and 5-year survival rate of 71, 33 and 19%, respectively. Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.

KW - Induction chemotherapy

KW - Malignant pleural mesothelioma

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=34249665493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249665493&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.02.004

DO - 10.1016/j.lungcan.2007.02.004

M3 - Article

C2 - 17403553

AN - SCOPUS:34249665493

VL - 57

SP - 89

EP - 95

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -